Completed Brain & Nervous System Psychology & Behaviour

Bridging the gap: biophysical models of human frontotemporal lobar degeneration

In plain English

AI plain-English summary

A single brain scan can now reveal the molecular wreckage of dementia while the patient is still alive—synaptic density, neurotransmitter levels, and the breakdown of neural circuits, all mapped in one person. This matters because dementia treatments fail when they target symptoms rather than the underlying biology. The gap between lab discoveries and patient care is enormous: scientists know how proteins misfold in a dish, but cannot explain why one person becomes apathetic while another loses language. This project closes that gap by building biophysical models of degenerating brain circuits, tested against real patient data from PET imaging, ultrahigh-field MR spectroscopy, and magnetoencephalography, then verified against post-mortem tissue. If successful, this approach could transform experimental medicine for frontotemporal dementia and progressive supranuclear palsy. Instead of trial-and-error drug testing, researchers could use these models to predict which patients will respond to which intervention, and measure whether a treatment actually restores synaptic function. The work is primarily fundamental science—building and validating mechanistic models of human cognitive disorders—but it is designed from the start for clinical translation, with longitudinal studies and pharmacological challenges already built into the programme.

View original technical description
To treat and prevent dementia in patients, it is essential to understand how microscopic changes in the human brain cause complex cognitive and behavioural disorders. My program addresses this critical gap in translational research, to facilitate clinical application of basic science discoveries. I have three goals, set in the context of frontotemproal dementia and progressive supranuclear palsy. First, I will develop quantitative biophysical models of human brain function that capture key cellular and pharmacological pathologies in vivo, with regional, laminar and synaptic specificity. These models of degenerating neuronal circuits are informed by individual measures of synaptic density (PET imaging with a SV2a ligand), GABA and glutamate (ultrahigh-field MR spectroscopy). They are optimised in vivo by inversion to magnetoencephalography, and tested post-mortem against neuropathology. This synergy of multi-modal imaging, together with Bayesian model comparison of Dynamic Casual Models, means one can drill down to the best mechanistic model of the human cognitive disorder. Second, I will show how harmful effects of dementia like apathy can be explained in terms of changes in synaptic density and loss of precision in hierarchical brain networks. Third, I will I demonstrate the readiness of my approach for experimental medicine, through longitudinal designs and pharmacological interventions.

View the original record at the funder ↗

Researchers

James Rowe (EPMC Awardee)

Related Research

Grants with similar aims, by meaning.

Imaging synaptic contributors to dementia
Restoring brain function: from cortical microcircuits to complex behaviours in neurodegenerative disease.
An interrogation of synaptic dysfunctions arising from human cognitive disease gene mutations using opto-physiological and neurochemical strategies.
Physiology of cognitive changes in ageing and dementia
From pathways to targets: Untangling the molecular mechanisms of neurodegeneration using ultra-sensitive optical imaging

Original classification

Investigator Award in Science

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.